Clinical Trials
77 trialsThiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Case Comprehensive Cancer Center
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
M.D. Anderson Cancer Center
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Weill Medical College of Cornell University
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Memorial Sloan Kettering Cancer Center
BMT CTN 0903
Medical College of Wisconsin
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
St. Jude Children's Research Hospital
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
University Hospital Schleswig-Holstein
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
University of Chicago
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Masonic Cancer Center, University of Minnesota
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Cord Blood Expansion on Mesenchymal Stem Cells
M.D. Anderson Cancer Center
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Beijing Immunochina Medical Science & Technology Co., Ltd.
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
University of Chicago
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Memorial Sloan Kettering Cancer Center
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
M.D. Anderson Cancer Center
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Memorial Sloan Kettering Cancer Center